Harmonized supportive care    (DrugBank: -)

2 diseases
IDDisease name (Link within this page)Number of trials
38Stevens-Johnson syndrome1
39Toxic epidermal necrolysis1

38. Stevens-Johnson syndrome    [ 11 clinical trials,   19 drugs,   (DrugBank: 8 drugs),   14 drug target genes,   98 drug target pathways]
Searched query = "Stevens-Johnson syndrome", "SJS", "Mucocutaneous ocular syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 11 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02987257
(ClinicalTrials.gov)
April 202125/11/2016NATIENS: Optimal Management and Mechanisms of SJS/TENNATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Toxic Epidermal NecrolysesDrug: Harmonized supportive care;Drug: Cyclosporine 5 mg/kg bid days 0-14;Drug: Etanercept 50 mg sc day 0 and day 3Vanderbilt University Medical CenterUniversity of Ottawa;University of TorontoNot yet recruiting18 YearsN/AAll267Phase 3United States

39. Toxic epidermal necrolysis    [ 11 clinical trials,   18 drugs,   (DrugBank: 8 drugs),   11 drug target genes,   101 drug target pathways]
Searched query = "Toxic epidermal necrolysis", "Toxic epidermal necrosis", "TEN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 11 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02987257
(ClinicalTrials.gov)
April 202125/11/2016NATIENS: Optimal Management and Mechanisms of SJS/TENNATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Toxic Epidermal NecrolysesDrug: Harmonized supportive care;Drug: Cyclosporine 5 mg/kg bid days 0-14;Drug: Etanercept 50 mg sc day 0 and day 3Vanderbilt University Medical CenterUniversity of Ottawa;University of TorontoNot yet recruiting18 YearsN/AAll267Phase 3United States